

Novel Predictor Of Mortality In Patients Undergoing Transcatheter Aortic Valve Implantation


Silvana Hamati, Mirko Doss, Christoph Liebetau, Thomas Walther.

Kerckhoff Heart Center Bad Nauheim, Bad Nauheim, Germany.

OBJECTIVE: There are no reliable biomarkers for short- or long-term outcome prediction in patients undergoing transcatheter aortic valve implantation (TAVI). Our goal was to investigate whether presepsin is also suited for risk assessment in TAVI patients. The aim of this study was to assess whether Presepsin, a novel marker indicative for sepsis, has prognostic value in the postoperative outcome in patients after transcatheter aortic valve implantation (TAVI).

METHODS: We included 72 patients undergoing TAVI in this single-center, observational study. We matched 31 patients who had died within 12 months after TAVI with 41 surviving patients with regards to age and major risk factors. Baseline presepsin levels were correlated to the hsTNT, the NT-proBNP, the ES II as well as to mortality after one year. Patients were selected in a non-randomised fashion. From all patients clinical data was reported and blood assessment was performed before and immediately after TAVI. From all patients informed consent is obtained and approval by the local ethics committee was achieved.

	AUC	SE *	95% CI †
Presepsin+ESII	0,811	0,0515	0,710 to 0,912
Presepsin	0,703	0,0837	0,579 to 0,828
ESII	0,687	0,0647	0,560 to 0,814



RESULTS: The Receiver operating characteristic curve (ROC) of presepsin and the various risk scores for the prediction of mortality after TAVI are presented in Figure 1. Presepsin provided the best result, with an area under the ROC curve of 0,703 vs. ES II with an AUC of 0,687. Comparing the predictive power of presepsin in addition to ES II showed the best predictive result with an AUC of 0,811. Presepsin provided the best result, with an area under the ROC curve of 0,703 vs. ES II with an AUC of 0,687. Comparing the predictive power of presepsin in Addition to ES II showed the best predictive result with an AUC of 0,811.

CONCLUSIONS: In summary, elevated presepsin levels are associated with significantly increased mortality after TAVI. Combining presepsin with ES II provides additive predictive value of risk stratification.

<http://heartvalvesociety.org/meeting/abstracts/2016/B40.cgi>